Lumicitabine - Alios BioPharma/Janssen

Drug Profile

Lumicitabine - Alios BioPharma/Janssen

Alternative Names: AL 8176; ALS 008176; ALS-8176; JNJ-1575; JNJ-64041575

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Janssen Research & Development
  • Class Antivirals; Furans; Nucleosides; Pyrimidines
  • Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections
  • Preclinical Metapneumovirus infections; Parainfluenza virus infections

Most Recent Events

  • 09 Nov 2017 Janssen Research & Development plans a phase II follow-up trial for Respiratory syncytial virus infections (In infants, In children) in USA, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Finland, France, Germany, Ireland, Israel, Japan, South Korea, Malaysia, New Zealand, Panama, Portugal, Slovakia, Spain, Sweden, Taiwan, Thailand, Ukraine and United Kingdom in November 2017 (NCT03332459)
  • 28 Jun 2017 Janssen initiates enrolment in a phase I pharmacokinetic trial in Germany (NCT03189498)
  • 21 Jun 2017 Janssen plans a pharmacokinetic phase I trial in Germany (NCT03189498)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top